Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 30 Jul 2009):

Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.

Full Abstract

BACKGROUND: This randomized, double blind trial determined the short and long-term clinical and hemodynamic vasodilator effects induced by percutaneous applications of natural CO2 gas in patients with moderate Fontaine stage II. PATIENTS AND METHODS: 62 patients with intermittent claudication (100-500 meters) were randomized to 18 consecutive days of CO2 treatment or placebo (air). The gas fluids were applied at a constant temperature of 30 degrees C on pre-humidified skin. The effects of the treatment were evaluated by total distance walked (primary criterion) and hemodynamic and microcirculatory findings. Patients also answered a quality of life questionnaire. RESULTS: The Strandness test showed a significant increase in total distance walked (+ 131 meters, 66%; p = 0.001) and pain-free distance (+ 81 meters, 73%; p = 0.02) after 18 days of CO2 treatment. The improvement was maintained 3 and 12 months later. The systolic pressure index (ABI) increased by 37% (p = 0.001) 1 minute after treadmill walking and ABI recovery time decreased significantly by 38% (p = 0.002). Microcirculatory findings showed an increase in systolic pressure of the great toe (13%; p < 0.0001), in baseline pO2 (20%; p = 0.01) and in vasomotion (78%; p = 0.001) in the treatment group. The improvement in total walking distance was correlated with the increase in ABI and peripheral cutaneous oxygenation. Patients' subjective assessments corroborated the benefits. No significant change was observed in the placebo group. CONCLUSIONS: This study demonstrates that 18 consecutive days of percutaneous CO2 treatment significantly increases walking distance in patients with moderate intermittent claudication. This effect, which was associated with an increase in peripheral systolic pressure and pO2, is evidence of a better ability to withstand effort.

 

Author information

Author/s: Fabry, R (R); Monnet, P (P); Schmidt, J (J); Lusson, J-R (JR); Carpentier, P-H (PH); Baguet, J-C (JC); Dubray, C (C);

Affiliation: Service therapeutique et Hydrologie Med., Faculté de Médicine, Clermont-Ferrand, France. regine.fabry(-atsign-)u-clermont.fr

Journal and publication information

Publication Type: Journal Article; Randomized Controlled Trial

Journal: VASA. Zeitschrift für Gefässkrankheiten. Journal for vascular diseases (Vasa), published in Switzerland. (Language: eng)

Reference: 2009-Aug; vol 38 (issue 3) : pp 213-24

Dates: Created 2009/09/08; Completed 2009/10/15;

PMID: 19736632, status: MEDLINE (last retrieval date: 10/15/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: Vasodilator Agents (0) ; Carbon Dioxide (124-38-9) ; Oxygen (7782-44-7)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

2/27/1981
10/30/2007
Higher Relevance Score (100)
Lower Relevance Score (64)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index